Since May 2014, an increase in Plasmodium vivax malaria has been observed in Sweden. As of 31 August 2014, 105 malaria cases have been reported in newly arrived Eritrean refugees, 84 of them P. vivax. The patients were mainly young men and reported migration through Ethiopia and/or Sudan. Severe anaemia and long symptom duration reflect inadequate healthcare during migration. Countries currently hosting Eritrean refugees need to consider P. vivax malaria in this group of migrants.
In Sweden, Plasmodium vivax accounts for 10 to 15% of the yearly ca 100 imported cases of malaria [1] . We report a dramatic increase in P. vivax cases among newly arrived Eritrean refugees, currently the third largest group of refugees in Sweden [2]. ; four patients had haemoglobin levels lower than 70 g/L and received blood transfusions. No other severe symptoms or deaths were reported. The diagnosis was established by conventional microscopy, and the patients were treated with chloroquine, except four patients who received artemether-lumefantrine (Riamet) due to initial uncertain species typing. All patients were prescribed relapse-preventing treatment with a 14-day course of primaquine, after excluding glucose-6-phosphate dehydrogenase deficiency.
Epidemiological hospital-based investigation

National surveillance data
A marked increase in the number of notified malaria cases was also observed at the Public Health Agency of Sweden. This notification is based on mandatory reporting from physicians and diagnostic laboratories according to the Communicable Disease Act (Figure 1 ).
Until 31 August, 237 cases of malaria have been reported in Sweden in 2014 (102 P. vivax, 77 P. falciparum, 12 P. ovale, two P. malariae, 44 unspecified species, and among those three mixed P. vivax and P. falciparum infections). According to the report from the notifying physician, 115 of them had been infected in Eritrea, Ethiopia and/or Sudan (72 P. vivax, seven P. falciparum, four P. ovale, 32 unspecified species and among those one mixed infection with P. vivax and P. falciparum). This corresponds to 9.0 P. vivax cases per month compared with 0.08 to 0.58 cases per month (between one and seven P. vivax cases annually) infected in those countries in the period 2010 to 2013 (Figure 2 ). There was no concomitant increase in P. falciparum cases.
By matching hospital and surveillance data, a total of 105 cases were confirmed to be Eritrean refugees (84 infected with P. vivax, five with P. falciparum, three with P. ovale and 13 with unspecified species). Some cases did not have the country of infection specified in the surveillance system, but were identified as Eritrean refugees in the complementary data provided by clinicians. Details on travel history, other than probable country, are usually not reported to the national surveillance system. Additional cases may therefore have occurred in this group, as well as among the cases where country of infection has not yet been reported. 
Migration and estimated incidence
Discussion
This increase in P. vivax malaria cases clustered in newly arrived Eritrean refugees is the largest increase malaria cases diagnosed in Sweden since the reporting to the Swedish Public Health Agency was computerised in 1986. In Sweden, as in other European countries, P. vivax is predominantly diagnosed in travellers who have visited Asia or Oceania [3] .
Although the number of asylum applications from Eritreans has increased in Sweden over the last years [2], the estimated P. vivax incidence was markedly higher in Eritreans who arrived in the past four months. The patients reported travelling through Ethiopia and/ or Sudan. We have not found any reports regarding ongoing outbreaks or markedly increased incidence of P. vivax malaria in those countries or in specific refugee camps over the past months. Nonetheless, our data suggest a high transmission of P. vivax along the route of migration of Eritrean refugees. P. vivax is endemic in more than 90 countries [6] , with the highest risk in Central Asia [7] . In sub-Saharan Africa, the parasite is endemic mainly on the Horn of Africa and Madagascar [6] , being geographically restricted by absence of Duffy antigens [8] . In Eritrea and Ethiopia, approximately 45% of malaria cases are due to P. vivax, compared with 5% in Sudan [6] . Eritrea reports a high rate of anti-malarial interventions and is considered to be on track to reduce malaria cases by more than 75% [6] . Malaria incidence had also decreased in Ethiopia over the last decade but there has been an increase in confirmed malaria cases including P. vivax in the past six years [6] . In Sudan, P. vivax transmission is limited and restricted to eastern and southern parts of the country [7] , the areas where many refugee camps are located [9] . Libya and Italy are considered malaria-free [6] . Several patients described that they and many fellow migrants had symptoms of malaria during the journey; some were treated in Ethiopia and some in Sudan. Although it is difficult to determine the source geographically, it is likely that our patients acquired the infection in Sudan, Ethiopia or Eritrea. Interestingly, although P. falciparum is the dominant species in those countries, the increase was specific for P. vivax. Geographical hotspots of transmission are likely to be situated along the route of migration, seeing as the P. vivax incidence among the refugees was higher than in Eritrea and Ethiopia (in 2012, one and seven per 1,000, respectively [6] ). The high incidence, especially among minors, could also suggest a larger malaria-naïve population due to reduced endemicity in Eritrea. This should however also apply for P. falciparum, which may have been cleared by previous antimalarial treatments in some of the patients, resulting mainly in P. vivax relapses.
Several patients were anaemic and in need of blood transfusions. Malarial anaemia is well described for P. vivax, especially after long symptom duration and/or repeated episodes [10] .
Conclusions
We report a high number of P. vivax malaria diagnosed in Sweden since May 2014. An increased incidence among newly arrived Eritrean refugees, especially in minors, indicates a change in exposure. Importantly, signs of long symptom duration during migration show the need for better healthcare for migrants and highlight the poor conditions that many refugees encounter during their escape. Countries currently hosting Eritrean refugees need to consider P. vivax malaria in these migrants.
*Erratum
The legend of Figure 2 was corrected on 5 September 2014. Blue and green were reversed.
